Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tipelukast - MediciNova

Drug Profile

Tipelukast - MediciNova

Alternative Names: KCA-757; MN-001

Latest Information Update: 30 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer MediciNova
  • Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Small molecules
  • Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene D4 receptor antagonists; Leukotriene receptor antagonists; Phospholipase C inhibitors; Thromboxane A2 receptor antagonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis
  • No development reported Interstitial cystitis
  • Discontinued Asthma

Most Recent Events

  • 23 Oct 2019 MediciNova receives patent allowance for tipelukast for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in Japan
  • 23 Oct 2019 MediciNova has a patent pending for tipelukast in Japan before October 2019
  • 07 Oct 2019 MediciNova receives patent allowance for tipelukast and MN 002 for the treatment of idiopathic pulmonary fibrosis in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top